Filing Details

Accession Number:
0000899243-20-018258
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-02 16:03:12
Reporting Period:
2020-06-30
Accepted Time:
2020-07-02 16:03:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1805890 Fusion Pharmaceuticals Inc. FUSN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1609405 Quang Chau Khuong C/O Fusion Pharmaceuticals Inc.
270 Longwood Road South
Hamilton A6 L8P 0A6
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2020-06-30 2,224,770 $0.00 2,224,770 No 4 C Indirect See Footnote
Common Shares Acquisiton 2020-06-30 705,900 $17.00 2,930,670 No 4 P Indirect See Footnote
Common Shares Acquisiton 2020-06-30 192,100 $17.00 192,100 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Class B Preferred Shares Disposition 2020-06-30 11,878,051 $0.00 2,224,770 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. The Class B Preferred Shares were convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, all Class B Preferred Shares converted into Common Shares.
  2. OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Capital LLC ("OrbiMed Capital") is a relying advisor of OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of OrbiMed Capital, GP VII, OrbiMed Advisors, and the Reporting Person disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein, if any.
  3. OrbiMed Capital is the investment advisor to OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPM.